In today’s recent session, 0.44 million shares of the Atossa Therapeutics Inc (NASDAQ:ATOS) have been traded, and its beta is 1.24. Most recently the company’s share price was $1.23, and it changed around -$0.05 or -3.91% from the last close, which brings the market valuation of the company to $154.74M. ATOS at last check was trading at a discount to its 52-week high of $2.31, offering almost -87.8% off that amount. The share price’s 52-week low was $0.67, which indicates that the recent value has risen by an impressive 45.53% since then. We note from Atossa Therapeutics Inc’s average daily trading volume that its 10-day average is 0.9 million shares, with the 3-month average coming to 570.28K.

Atossa Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ATOS as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Atossa Therapeutics Inc is expected to report earnings per share of -0.06 for the current quarter.

Atossa Therapeutics Inc (NASDAQ:ATOS) trade information

Instantly ATOS has been showing red trend so far today with a performance of -3.91% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.4100 on recent trading dayincreased the stock’s daily price by 12.77%. The company’s shares are currently up 39.77% year-to-date, but still down -10.22% over the last five days. On the other hand, Atossa Therapeutics Inc (NASDAQ:ATOS) is -18.00% down in the 30-day period. We can see from the shorts that 12.77 million shares have been sold at a short interest cover period of 30.34 day(s).

The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 75.4% from its current value. Analyst projections state that ATOS is forecast to be at a low of $5 and a high of $5.

Atossa Therapeutics Inc (ATOS) estimates and forecasts

Atossa Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -19.61 percent over the past six months and at a 12.50% annual growth rate that is well below the industry average of 15.40%.

Forecasts for the next quarter put sales growth at �.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 46.61%.

ATOS Dividends

Atossa Therapeutics Inc’s next quarterly earnings report is expected to be released in December.

Atossa Therapeutics Inc (NASDAQ:ATOS)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 0.06% of Atossa Therapeutics Inc shares, and 28.23% of them are in the hands of institutional investors. The stock currently has a share float of 28.24%. Atossa Therapeutics Inc stock is held by 113.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 7.3389% of the shares, which is about 9.2 million shares worth $10.94 million.

VANGUARD GROUP INC, with 5.1755% or 6.49 million shares worth $7.72 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Jun 30, 2024. The former held 3.94 shares worth $4.85 million, making up 3.13% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 3.3 shares worth around $4.06 million, which represents about 2.63% of the total shares outstanding.